I alle fire undersøgelser viste kombinationen af rosiglitazon og glimeprid sig at være mere effektiv end hver af dets komponenter anvendt alene til sænkning af niveauerne af HbA1c.
In all four studies, the combination of rosiglitazone and glimepride was shown to be more effective than either of its components used on its own in lowering the levels of HbA1c.